Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Additional Listing

1 May 2014 16:37

RNS Number : 1150G
Epistem Holdings plc
01 May 2014
 



 

 

Epistem Holdings Plc

Additional Listing

Epistem (AIM: EHP) announces that 239,666 new ordinary shares of 1.5 pence each (the "New Ordinary Shares") have been issued and allotted pursuant to the exercise of options under the Epistem Holdings Plc EMI Share Option Scheme.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 8th May, 2014 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following the admission to trading of the New Ordinary Shares, Epistem will have 10,004,906 ordinary shares of 1.5 pence each in issue.

 

 

For further details please contact:

 

Epistem Plc

Matthew Walls, CEO +44 161 606 7258

John Rylands, Finance Director +44 161 606 7244

 

Peel Hunt LLP

James Steel +44 20 7418 8900

Clare Terlouw

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISUGUPWAUPCGAG
Date   Source Headline
25th Apr 20229:00 amRNSPrice Monitoring Extension
20th Apr 20222:00 pmRNSPrice Monitoring Extension
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:35 pmRNSPrice Monitoring Extension
4th Apr 20225:13 pmRNSDirector/PDMR Shareholding
4th Apr 202211:05 amRNSSecond Price Monitoring Extn
4th Apr 202211:00 amRNSPrice Monitoring Extension
4th Apr 20229:05 amRNSSecond Price Monitoring Extn
4th Apr 20229:00 amRNSPrice Monitoring Extension
31st Mar 20229:05 amRNSSecond Price Monitoring Extn
31st Mar 20229:00 amRNSPrice Monitoring Extension
29th Mar 202211:06 amRNSSecond Price Monitoring Extn
29th Mar 202211:00 amRNSPrice Monitoring Extension
29th Mar 202210:00 amRNSNICE issues Medtech Innovation Briefing
29th Mar 20227:00 amRNSHalf-year Report
25th Mar 202211:05 amRNSSecond Price Monitoring Extn
25th Mar 202211:00 amRNSPrice Monitoring Extension
24th Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20224:41 pmRNSSecond Price Monitoring Extn
22nd Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20223:16 pmRNSPALOH study results published in JAMA Pediatrics
21st Mar 20229:05 amRNSSecond Price Monitoring Extn
21st Mar 20229:00 amRNSPrice Monitoring Extension
18th Mar 20224:41 pmRNSSecond Price Monitoring Extn
18th Mar 20224:36 pmRNSPrice Monitoring Extension
18th Mar 20222:05 pmRNSSecond Price Monitoring Extn
18th Mar 20222:00 pmRNSPrice Monitoring Extension
18th Mar 20222:00 pmRNSFirst NHS Deployments of Genedrive System for AIHL
17th Mar 20227:00 amRNSBoard appointment
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:35 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSFurther re Directorate Change
23rd Feb 20225:00 pmRNSDirector/PDMR Shareholding
23rd Feb 20229:05 amRNSSecond Price Monitoring Extn
23rd Feb 20229:00 amRNSPrice Monitoring Extension
23rd Feb 20227:00 amRNSUpdate on Point of Care Covid Test
15th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSNotice of Results
21st Jan 202211:05 amRNSSecond Price Monitoring Extn
21st Jan 202211:00 amRNSPrice Monitoring Extension
20th Jan 20224:40 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
10th Jan 20229:06 amRNSSecond Price Monitoring Extn
10th Jan 20229:00 amRNSPrice Monitoring Extension
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:01 pmRNSPrice Monitoring Extension
30th Dec 202111:20 amRNSResult of AGM
30th Dec 20219:05 amRNSSecond Price Monitoring Extn
30th Dec 20219:00 amRNSPrice Monitoring Extension
22nd Dec 202111:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.